Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor alpha (TNF alpha) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repeated treatment with a chimeric monoclonal antibody to TNF alpha (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.

Original publication




Journal article


Lancet (London, England)

Publication Date





1125 - 1127


Kennedy Institute of Rheumatology, Hammersmith, London, UK.


Humans, Arthritis, Rheumatoid, Recurrence, Tumor Necrosis Factor-alpha, C-Reactive Protein, Antibodies, Monoclonal, Infusions, Intravenous, Dose-Response Relationship, Immunologic, Infliximab